腹膜透析期间的妥布霉素浓度。
Tobramycin concentrations during peritoneal dialysis.
作者信息
Weinstein A J, Karchmer A W, Moellering R C
出版信息
Antimicrob Agents Chemother. 1973 Oct;4(4):432-4. doi: 10.1128/AAC.4.4.432.
Abstract
A patient undergoing peritoneal dialysis for severe renal failure was treated with tobramycin. Peritoneal dialysis was inefficient in removing tobramycin from the serum. Tobramycin concentrations in the dialysis effluent were low. Despite acute oliguric renal failure, urine concentrations of tobramycin were sufficient to treat most gram-negative urinary tract infections.
摘要
一名因严重肾衰竭接受腹膜透析的患者接受了妥布霉素治疗。腹膜透析在从血清中清除妥布霉素方面效率低下。透析流出液中的妥布霉素浓度较低。尽管存在急性少尿性肾衰竭，但尿液中的妥布霉素浓度足以治疗大多数革兰氏阴性菌引起的尿路感染。
相似文献
1
Tobramycin concentrations during peritoneal dialysis.
Antimicrob Agents Chemother. 1973 Oct;4(4):432-4. doi: 10.1128/AAC.4.4.432.
2
3
Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin.
Antimicrob Agents Chemother. 1975 Nov;8(5):574-80. doi: 10.1128/AAC.8.5.574.
4
Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.
Antimicrob Agents Chemother. 1974 Jun;5(6):611-6. doi: 10.1128/AAC.5.6.611.
5
Clinical and laboratory studies with tobramycin.
Chemotherapy. 1974;20(4):245-56. doi: 10.1159/000221814.
6
Effect of peritoneal dialysis solution on the antimicrobial activity of cephalosporins.
Nephron. 1982;30(4):341-4. doi: 10.1159/000182513.
7
Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis.
J Am Soc Nephrol. 2000 Jul;11(7):1310-1316. doi: 10.1681/ASN.V1171310.
8
Tobramycin kinetics during continuous ambulatory peritoneal dialysis.
Clin Pharmacol Ther. 1983 Jul;34(1):110-6. doi: 10.1038/clpt.1983.138.
9
Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.
Antimicrob Agents Chemother. 1973 Jan;3(1):125-9. doi: 10.1128/AAC.3.1.125.
10
Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.
Antimicrob Agents Chemother. 2004 May;48(5):1719-26. doi: 10.1128/AAC.48.5.1719-1726.2004.
引用本文的文献
1
Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.
Antimicrob Agents Chemother. 1974 Jun;5(6):611-6. doi: 10.1128/AAC.5.6.611.
2
Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin.
Antimicrob Agents Chemother. 1975 Nov;8(5):574-80. doi: 10.1128/AAC.8.5.574.
3
Antibiotic penetrance of ascitic fluid in dogs.
Antimicrob Agents Chemother. 1976 Nov;10(5):850-5. doi: 10.1128/AAC.10.5.850.
4
Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.
Drugs. 1976;12(3):166-200. doi: 10.2165/00003495-197612030-00002.
本文引用的文献
1
GENTAMICIN: ACTIVITY IN VITRO AND OBSERVATIONS IN 26 PATIENTS.
Am J Med Sci. 1964 Nov;248:528-44.
2
Preliminary studies with nebramycin factor 6.
Antimicrob Agents Chemother (Bethesda). 1970;10:314-21.
3
Correlation of serum creatinine concentration and gentamicin half-life.
JAMA. 1972 Feb 21;219(8):1037-41.
4
Preclinical assessment of the antibacterial activity of nebramycin factor 6.
Antimicrob Agents Chemother (Bethesda). 1970;10:322-7. doi: 10.1128/AAC.10.2.322.
5
Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.
Antimicrob Agents Chemother. 1973 Jan;3(1):125-9. doi: 10.1128/AAC.3.1.125.
6
Tobramycin: in vitro activity and comparison with kanamycin and gentamicin.
Antimicrob Agents Chemother. 1972 Apr;1(4):340-2. doi: 10.1128/AAC.1.4.340.
7
In vitro studies of tobramycin, an aminoglycoside antibiotic.
Antimicrob Agents Chemother. 1972 Jan;1(1):41-5. doi: 10.1128/AAC.1.1.41.
Zotero 插件